Microbiología y parasitología
Especialidad
Hospital de Mataró
Barcelona, EspañaPublications en collaboration avec des chercheurs de Hospital de Mataró (14)
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
Correction to: The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients (Critical Care, (2021), 25, 1, (331), 10.1186/s13054-021-03727-x)
Critical Care
-
HIV/HBV coinfection: Temporal trends and patient characteristics, Spain, 2002 to 2018
Eurosurveillance, Vol. 26, Núm. 25
-
The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients
Critical Care, Vol. 25, Núm. 1
2020
-
First national survey of the diagnosis of Helicobacter pylori infection in Clinical Microbiology Laboratories in Spain
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 9, pp. 410-416
2018
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Comprehensive clinical and epidemiological assessment of colonisation and infection due to carbapenemase-producing Enterobacteriaceae in Spain
Journal of Infection, Vol. 72, Núm. 2, pp. 152-160
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2012
2010
-
Inhaled drugs as risk factors for communityacquired pneumonia
European Respiratory Journal, Vol. 36, Núm. 5, pp. 1080-1087
2008
-
New evidence of risk factors for community-acquired pneumonia: A population-based study
European Respiratory Journal, Vol. 31, Núm. 6, pp. 1274-1284